A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.

PHASE3TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

March 13, 2023

Primary Completion Date

September 24, 2025

Study Completion Date

September 24, 2025

Conditions
Duchenne Muscular Dystrophy
Interventions
BIOLOGICAL

fordadistrogene movaparvovec

gene therapy administered in a previous study.

Trial Locations (12)

27705

Duke Lenox Baker Children's, Durham

27710

Duke Children's Health Center, Durham

84108

University of Utah Imaging and Neurosciences Center, Salt Lake City

84112

University of Utah Hospital, Salt Lake City

84113

Primary Children's Hospital, Salt Lake City

84132

University of Utah Clinical Neurosciences Center, Salt Lake City

University of Utah Craig H. Neilsen Rehabilitation Hospital, Salt Lake City

90095

Reed Neurological Research Center, Los Angeles

UCLA Children's Heart Center, Los Angeles

UCLA Clinical Lab Services, Los Angeles

UCLA Kameron Gait and Motion Analysis Laboratory (Westwood Rehabilitation Center), Los Angeles

UCLA Medical Center, Los Angeles

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05689164 - A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy. | Biotech Hunter | Biotech Hunter